On Tuesday, Acadia Healthcare Company Inc (NASDAQ:ACHC)’s shares declined -2.90% to $77.89.
Acadia Healthcare Company, Inc. (ACHC) declared financial results for the second quarter and six months ended June 30, 2015. For the quarter, revenue raised 112.2% to $453.7 million from $213.8 million for the second quarter of 2014. Income from ongoing operations was $33.8 million, or $0.49 per diluted share, for the second quarter of 2015 contrast with $22.5 million, or $0.43 per diluted share, for the second quarter of 2014. Adjusted income from ongoing operations raised 137.8% to $39.5 million for the second quarter of 2015 from $16.6 million for the second quarter of 2014, while adjusted income from ongoing operations per diluted share raised 78.1% to $0.57 from $0.32. The adjusted results exclude transaction-related expenses of $7.2 million and $3.0 million for the second quarter of 2015 and 2014, respectively, a $1.0 million loss on foreign currency derivatives for the second quarter of 2015 and a $13.7 million gain on foreign currency derivatives for the second quarter of 2014. Weighted average shares outstanding raised 32.6% for the second quarter of 2015 from the second quarter of 2014, primarily due to the issuance of common stock in June 2014 and February and May 2015, the net proceeds of which have primarily been used to fund acquisitions. A reconciliation of all non-GAAP financial results in this release appears on pages 8 and 9.
For the first six months of 2015, revenue grew 97.4% to $819.4 million from $415.2 million for the first six months of 2014. Income from ongoing operations for the first half of 2015 was $48.4 million, or $0.74 per diluted share, contrast with $35.5 million, or $0.69 per diluted share, for the same period in 2014. Adjusted income from ongoing operations raised 117.5% to $66.6 million for the first six months of 2015 from $30.6 million for the first six months of 2014, while adjusted income from ongoing operations per diluted share raised 68.3% to $1.01 from $0.60. The adjusted results exclude transaction-related expenses of $25.6 million and $4.6 million for the first half of 2015 and 2014, respectively, a $0.9 million loss on foreign currency derivatives for the first half of 2015 and a $13.7 million gain on foreign currency derivatives for the first half of 2014. Weighted average shares outstanding raised 28.5% for the first six months of 2015 contrast with the same period in 2014.
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, and substance abuse facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico. Its acute inpatient psychiatric facilities offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities comprise residential recovery facilities, eating disorder facilities, and comprehensive treatment centers providing a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers treat patients with behavioral disorders in a non-hospital setting, counting outdoor programs.
STMicroelectronics NV (ADR) (NYSE:STM)’s shares dropped -1.76% to $7.53.
STMicroelectronics (STM), a global semiconductor leader serving customers across the spectrum of electronics applications, declared the STiD325 (codenamed Barcelona), its DOCSIS[1] 3.1 chipset for Broadband CPE[2] Cable Modems, embedded Media Terminal Adapters (eMTAs), and Gateways, in addition to for Video Gateways when associated to set-top-box chipsets. It is being demonstrated at CableLabs Summer Conference, August 2-5, 2015 in Keystone, Colorado, USA.
DOCSIS 3.1 has been engineered by CableLabs(R) to unleash the multi-gigabit data era on existing Hybrid Fiber-Coax (HFC) netoperates through improved spectral efficiency using OFDM[3] multi-carrier modulation combined with low-density parity-check-based Forward Error Correction.
Designed for economy and performance, Barcelona features solid technical capabilities:
- Very high performance using multiple 64-bit ARM(R)CPUs to deliver >10K DMIPS, line-rate networking support on every port, and hardware acceleration for routing and switching, allowing Multiple System Operators (MSOs) to build future-proof CPE platforms with plenty of headroom to support the field introduction of new services;
- Backward compatibility with DOCSIS 3.0 32×8 to allow a smooth, cost-effective transition to DOCSIS 3.1;
- Flexible architecture facilitating independent software development and software upgrades with minimal coupling between stacks, in addition to the introduction of new features like home surveillance and home automation; support of various Wi-Fi configurations;
- 28nm FD-SOI silicon technology, providing outstanding power efficiency at all operating levels, counting fan-less designs, together with highly-efficient RF and analog integration.
Presently sampling to lead customers, Barcelona comes with pre-integrated RDK-B software, counting DOCSIS and Packet-Cable stacks.
STMicroelectronics N.V. designs, develops, manufactures, and markets various semiconductor integrated circuits and discrete devices worldwide. The company offers a range of semiconductor products, counting discrete and standard commodity components, application-specific integrated circuits, full-custom devices and semi-custom devices, micro-electro-mechanical systems, microcontrollers, sensors, digital consumer products, imaging products, memory products, media application processors, and application-specific standard products for analog, digital, and mixed-signal applications, in addition to silicon chips and smartcards.
At the end of Tuesday’s trade, Kulicke and Soffa Industries Inc. (NASDAQ:KLIC)‘s shares surged 0.50% to $10.14.
Kulicke and Soffa Industries, Inc. (KLIC) declared results for its third fiscal quarter ended June 27, 2015.
Third Quarter Fiscal 2015 Key Product Trends
- Ball bonder equipment net revenue raised 15.9% over the March quarter.
- 7% of ball bonder equipment was sold as copper capable.
- Wedge bonder equipment net revenue raised by 4.8% over the March quarter.
- Advanced Packaging Mass Reflow equipment net revenue raised by 24.4% over the March quarter.
Third Quarter Fiscal 2015 Financial Highlights
- Net revenue of $164.6 million.
- Gross margin of 47.1%.
- Net income of $25.0 million or $0.33 per share comprises favorable tax benefits totaling $13.7 million or $0.18 per share.
- Cash and cash equivalents were $475.9 million as of June 27, 2015.
Fourth Quarter Fiscal 2015 Outlook
The Company presently anticipates net revenue in the fourth fiscal quarter of 2015, ending October 3, 2015, to be in the range of about $135 million to $145 million.
Kulicke and Soffa Industries, Inc. designs, manufactures, and sells capital equipment and expendable tools to assemble semiconductor devices, counting integrated circuits, discrete devices, light-emitting diodes (LED), and power modules. It operates in two segments, Equipment and Expendable Tools. The Equipment segment manufactures and sells a line of ball bonders to connect very fine wires made of gold or copper between the bond pads of the semiconductor devices or dies, and the leads on its package; wafer level bonders, which mechanically applies bumps to dies for some variants of the flip chip assembly process; heavy wire wedge bonders to connect semiconductor chips for the power packages, power hybrids, and automotive modules; and manual wire bonders, in addition to offers spare parts, equipment repair, and training services.
Synthetic Biologics Inc (NYSEMKT:SYN), ended its Tuesday’s trading session with -1.55% loss, and closed at $3.18.
Synthetic Biologics, Inc. (SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June 30, 2015 on Monday, August 10, 2015, and to host a conference call the same day at 8:30 a.m. EDT.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
